My Adrenal Tumors Journey Chapter 4: What the Scope Found | v64otd.com

My Adrenal Tumors Journey Chapter 4: What the Scope Found

SERIES My Adrenal Tumor Journey

Part 4 of the series

A PA who moved fast, a doctor who wasn't worried, and a pathology report that had something to say about both of those calls.

Originally published on Substack. Imported to My Ledger as part of the adrenal journey series.

Quick recap for anyone just joining: Chapter 1 covered fifteen years of diagnoses that turned out to share a single cause nobody connected. Chapter 2 covered the diagnosis itself — bilateral adrenal adenomas, Cushing’s Syndrome confirmed, and a multidisciplinary team at UT Southwestern reviewing the case together. Chapter 3 covered a GI visit where I brought six pages of prepared questions and left with five unanswered, a set of labs that nobody walked me through, and a voicemail recommending an upper endoscopy that arrived almost at the same time as my Google review.

This chapter is about what happened when I actually got that endoscopy — and what it found.

Why was I there in the first place

I want to be clear about something the chapter order might obscure: I didn’t go to my GI practice because of the Cushing’s diagnosis. I went because of an iron deficiency and low B12 that weren’t resolving — two problems documented in the labs that I wanted a GI specialist’s judgment on, because persistent malabsorption issues belong in that specialty’s lane.

That didn’t go the way I expected. From the initial appointment, the message I came away with was that there wasn’t really a problem worth pursuing yet. The iron deficiency wasn’t concerning enough to act on. The B12 picture wasn’t alarming. Unless I had symptoms — clear, present, unambiguous symptoms — the posture was essentially watchful waiting with nothing to watch.

I had brought more than just the lab numbers. I’m also diabetic and on Mounjaro, which is a GLP-1 receptor agonist known to slow gastric emptying as part of how it works. I had a real question: whether that delayed emptying, combined with whatever was happening with my stomach acid, might be creating an absorption environment that explained why oral supplementation wasn’t moving my numbers. That felt like exactly the kind of drug-condition-lab interaction a GI specialist should want to think through. It didn’t get much traction.

I also mentioned one thing I thought might qualify as a symptom: occasional pain up under my left rib cage, particularly after a large meal or something heavy — Mexican food being the reliable example. Not constant, not severe, but present and consistent enough that I’d noticed the pattern.

I also asked, directly, for an upper endoscopy. The answer was no. Not indicated. Not necessary at this point.

At almost exactly fifteen minutes into the appointment, the PA stood up. The visit was over. What I was left with was an order for an abdominal ultrasound — a test that came back with findings the original CT scan from June had not shown at all. The June CT had reported the liver as homogeneous throughout, without focal lesions. The September ultrasound revealed something different: fatty infiltration of the liver; a 1.6 x 2.0 x 1.6-centimeter hypoechoic mass in the left lobe, described as non-cystic and possibly a hemangioma or other mass; and an enlarged spleen.

I wasn’t expecting liver findings. That’s worth saying plainly, because it captures something about how this whole process has gone: I came in about iron and B12, and left with a liver that needs a second look. A formal diagnosis hasn’t been made, but the picture is trending toward NASH — non-alcoholic steatohepatitis, a form of liver disease driven by fat accumulation and inflammation rather than alcohol. I don’t drink. What I do have is years of uncontrolled hypercortisolism, which is a well-documented driver of fatty liver disease through its effects on fat metabolism, insulin resistance, and visceral fat distribution. One more system. One more thread leading back to the same place.

The callback

Two days later, my phone rang. It was the practice. The PA had spoken with the doctor directly, and the doctor had agreed: an upper endoscopy was now recommended after all.

I want to sit with that for a moment, because I think it deserves honest examination rather than a clean narrative.

One interpretation is straightforward and generous: the PA presented my case to the physician, the physician reviewed it with fresh eyes, and a more experienced clinician concluded that the scope was warranted. That’s exactly how the system is supposed to work, and if that’s what happened, it worked. I’m glad it did.

The other interpretation is harder to dismiss entirely, and I think anyone who’s spent time navigating the American healthcare system will recognize it: an endoscopy is a billable procedure. A patient who leaves unhappy and writes about their experience is a risk. I had already left the Google review documented in Chapter 3 by that point. I don’t know the exact timing of the callback relative to when that review was posted. I don’t have enough information to draw a conclusion, and I’m not going to pretend I do.

What I’m left with is the same thing Chapter 3 ended on: both interpretations are entirely plausible. I’m noting the sequence here, not accusing anyone of anything. The reader can draw their own conclusions about which story fits the pattern this series has been documenting.

Getting to the room

When the endoscopy was scheduled, I prepared the same way I’ve prepared for every significant appointment in this process: a written summary of my symptoms, my relevant history, and the specific questions I needed answered. The pre-procedure appointment covered the scope logistics and moved efficiently through the clinical checklist. The larger picture I kept trying to bring into the frame — whether something structural in my stomach might be explaining more than one problem at once — kept falling on deaf ears.

I went into the endoscopy without a lot of reassurance. That turned out to be the right posture.

What they found

The pathology report came back with findings specific enough to belong in this series — not because I want to turn a medical record into a grievance, but because what the tissue showed is exactly what the questions I’d been asking were aimed at all along.

The report documented ECL cell hyperplasia, focal mucosal atrophy, and focal intestinal metaplasia.

If those terms are unfamiliar — they were to me too, until recently — here’s what they mean in plain language:

ECL cell hyperplasia is an overgrowth of a specific type of cell in the stomach lining that produces histamine to trigger acid secretion. When those cells proliferate abnormally, it’s usually because the stomach isn’t producing enough acid on its own, and the body compensates by working the system harder. It’s also a known precursor to a type of gastric carcinoid tumor, which gets monitored closely once it’s identified.

Focal mucosal atrophy means sections of the stomach lining have thinned and lost functional cells — specifically parietal cells, which produce stomach acid and intrinsic factor. Intrinsic factor is what allows B12 to be absorbed. No functioning intrinsic factor, no B12 absorption, regardless of how much you supplement orally. This finding, sitting next to months of oral iron supplementation that barely moved my numbers, reframed a question I’d been asking since the very first appointment.

Focal intestinal metaplasia means sections of the stomach lining have been replaced by cells that resemble intestinal tissue rather than gastric tissue. It’s a precancerous change that requires ongoing surveillance, and its presence alongside the other two findings points to a pattern rather than an isolated anomaly.

Taken together, the working picture emerging from these findings has a name: Autoimmune Metaplastic Atrophic Gastritis. AMAG. An autoimmune condition in which the immune system attacks the stomach’s parietal cells, progressively destroying the architecture of the gastric lining over time. It explains the B12 absorption failure. It explains why oral iron wasn’t moving the needle on my numbers. It explains the pain under the left rib cage after a heavy meal. A stomach with compromised acid production and damaged mucosal architecture doesn’t handle large fat and carbohydrate loads the way a healthy one does. And it reframes the Mounjaro question I’d raised at the start: the delayed gastric emptying I was already asking about wasn’t the whole story, but it was pointing in the right direction. The stomach wasn’t working right. The question was always worth asking.

The original reason I walked into that practice was iron deficiency and low B12 that weren’t resolving. The pathology report had an explanation for both. It just took a scope and a biopsy to find it — and a callback two days after a dismissal to get the scope scheduled in the first place.

The part that keeps coming back to me

I want to be fair here, because this series has tried to be fair throughout. The endoscopy was ordered, the procedure happened, and the findings exist because someone made that call. That matters.

But I keep coming back to the appointment that ended at fifteen minutes. To the iron and B12 questions that weren’t worth pursuing. To the Mounjaro absorption question that didn’t get traction. To the rib cage pain that didn’t move the needle. To the endoscopy request that was declined, then reversed 48 hours later, after a conversation I wasn’t part of.

I’m not drawing a straight line between any of that and what the pathology report said. I’m not qualified to make that call. What I’m noting is that the questions were right, the symptom was real, the request was reasonable, and the answer was still no — until, for whatever reason, it wasn’t.

The reader can decide what that sequence means. I’ve stopped being surprised by it.

Where this fits in the larger picture

AMAG is an autoimmune condition. I now have documented autoimmune activity at the gastric level, elevated TPO antibodies suggesting autoimmune predisposition at the thyroid, hip arthritis in a joint that was never injured, and years of uncontrolled hypercortisolism sitting underneath all of it.

Chronic cortisol excess affects the immune system in a specific way. It suppresses certain immune pathways while dysregulating others — shifting the balance in a direction associated in the research literature with increased autoimmune antibody production. It also directly damages the gut mucosal barrier, which can expose the immune system to antigens it wouldn’t normally encounter and amplify autoimmune responses that might otherwise remain latent. I’m not citing my own case as evidence of that mechanism. I’m noting that the mechanism exists, it’s documented, and my case is becoming a fairly thorough illustration of what it looks like when nobody steps back far enough to see the whole picture until year fifteen.

The AVS is on October 26th. October 12th is a follow-up to review the endoscopy findings in detail and determine the GI management plan from here. There are surveillance intervals to establish, antibody panels that haven’t been ordered yet, and at least one referral conversation I’m planning to have that hasn’t happened yet.

There is a broader failure worth naming here, because this series has been circling it for four chapters without saying it outright. The specialists involved in my care are, individually, competent people doing their jobs within their defined lanes. That is precisely the problem. My endocrinologist manages the adrenals. My GI practice manages the digestive tract. Nobody’s job description includes standing back far enough to see that years of excess cortisol damages the gut mucosal barrier, drives autoimmune dysregulation, causes fatty liver disease, impairs absorption of the very nutrients that keep everything else functioning, and deposits fat in places that create their own downstream problems — and that all of those things are therefore connected, active, and relevant to each other right now. That’s not a gap any of them created. It’s a gap the system created by design, and then handed to the patient to manage alone.

I’ll add one more observation that I’ve been sitting with: I’m not sure what my primary care physician is for anymore. I don’t need referrals. My specialists refer to each other when they refer at all. What I actually need is someone whose job it is to hold the entire picture at once. To look at an endocrinology finding and ask what it means for GI, to look at a GI finding and ask what it means for absorption and surgery planning, to look at a liver finding and ask what it means for everything else already in motion. And then to take one more step and ask: given all of this, what else might be going on that nobody has looked for yet? That person should exist. In a well-functioning system, that person is the primary care physician. What I have instead is a collection of specialists who each own one piece, stay inside that piece, and hand the patient back with a follow-up appointment scheduled, and no one asks the next question. The job exists. It just has no one in it.

I am not a doctor. I should not be the person holding all of this together. I am doing it anyway, because the alternative is that nobody does.

I’m still the one with all three specialists’ calendars open at the same time. What still catches me a little off guard, even now, is opening a pathology report and finding that the questions you came in with, written on a piece of paper, were the right ones all along.

Chapter 5 is whenever October 12th, the Fibroscan, the AVS, or what follows, gives me something worth writing about. Probably sooner than I’d like.